1 Non-prescription Drugs Market Overview
1.1 Product Overview and Scope of Non-prescription Drugs
1.2 Non-prescription Drugs Segment by Type
1.2.1 Global Non-prescription Drugs Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Brand Drugs
1.2.3 Generic Drug
1.3 Non-prescription Drugs Segment by Application
1.3.1 Global Non-prescription Drugs Sales Comparison by Application: (2022-2028)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Non-prescription Drugs Market Size Estimates and Forecasts
1.4.1 Global Non-prescription Drugs Revenue 2017-2028
1.4.2 Global Non-prescription Drugs Sales 2017-2028
1.4.3 Non-prescription Drugs Market Size by Region: 2017 Versus 2021 Versus 2028
2 Non-prescription Drugs Market Competition by Manufacturers
2.1 Global Non-prescription Drugs Sales Market Share by Manufacturers (2017-2022)
2.2 Global Non-prescription Drugs Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Non-prescription Drugs Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Non-prescription Drugs Manufacturing Sites, Area Served, Product Type
2.5 Non-prescription Drugs Market Competitive Situation and Trends
2.5.1 Non-prescription Drugs Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Non-prescription Drugs Players Market Share by Revenue
2.5.3 Global Non-prescription Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Non-prescription Drugs Retrospective Market Scenario by Region
3.1 Global Non-prescription Drugs Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Non-prescription Drugs Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Non-prescription Drugs Market Facts & Figures by Country
3.3.1 North America Non-prescription Drugs Sales by Country
3.3.2 North America Non-prescription Drugs Revenue by Country
3.3.3 the United States
3.3.4 Canada
3.4 Europe Non-prescription Drugs Market Facts & Figures by Country
3.4.1 Europe Non-prescription Drugs Sales by Country
3.4.2 Europe Non-prescription Drugs Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 UK
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Non-prescription Drugs Market Facts & Figures by Region
3.5.1 Asia Pacific Non-prescription Drugs Sales by Region
3.5.2 Asia Pacific Non-prescription Drugs Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 China Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America Non-prescription Drugs Market Facts & Figures by Country
3.6.1 Latin America Non-prescription Drugs Sales by Country
3.6.2 Latin America Non-prescription Drugs Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Non-prescription Drugs Market Facts & Figures by Country
3.7.1 Middle East and Africa Non-prescription Drugs Sales by Country
3.7.2 Middle East and Africa Non-prescription Drugs Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Non-prescription Drugs Historic Market Analysis by Type
4.1 Global Non-prescription Drugs Sales Market Share by Type (2017-2022)
4.2 Global Non-prescription Drugs Revenue Market Share by Type (2017-2022)
4.3 Global Non-prescription Drugs Price by Type (2017-2022)
5 Global Non-prescription Drugs Historic Market Analysis by Application
5.1 Global Non-prescription Drugs Sales Market Share by Application (2017-2022)
5.2 Global Non-prescription Drugs Revenue Market Share by Application (2017-2022)
5.3 Global Non-prescription Drugs Price by Application (2017-2022)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Non-prescription Drugs Sales, Revenue and Gross Margin (2017-2022)
6.1.4 Pfizer Non-prescription Drugs Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Roche
6.2.1 Roche Corporation Information
6.2.2 Roche Description and Business Overview
6.2.3 Roche Non-prescription Drugs Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Roche Non-prescription Drugs Product Portfolio
6.2.5 Roche Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Corporation Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Non-prescription Drugs Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Sanofi Non-prescription Drugs Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Johnson & Johnson
6.4.1 Johnson & Johnson Corporation Information
6.4.2 Johnson & Johnson Description and Business Overview
6.4.3 Johnson & Johnson Non-prescription Drugs Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Johnson & Johnson Non-prescription Drugs Product Portfolio
6.4.5 Johnson & Johnson Recent Developments/Updates
6.5 Merck & Co. (MSD)
6.5.1 Merck & Co. (MSD) Corporation Information
6.5.2 Merck & Co. (MSD) Description and Business Overview
6.5.3 Merck & Co. (MSD) Non-prescription Drugs Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Merck & Co. (MSD) Non-prescription Drugs Product Portfolio
6.5.5 Merck & Co. (MSD) Recent Developments/Updates
6.6 Novartis
6.6.1 Novartis Corporation Information
6.6.2 Novartis Description and Business Overview
6.6.3 Novartis Non-prescription Drugs Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Novartis Non-prescription Drugs Product Portfolio
6.6.5 Novartis Recent Developments/Updates
6.7 AbbVie
6.6.1 AbbVie Corporation Information
6.6.2 AbbVie Description and Business Overview
6.6.3 AbbVie Non-prescription Drugs Sales, Revenue and Gross Margin (2017-2022)
6.4.4 AbbVie Non-prescription Drugs Product Portfolio
6.7.5 AbbVie Recent Developments/Updates
6.8 Gilead Sciences
6.8.1 Gilead Sciences Corporation Information
6.8.2 Gilead Sciences Description and Business Overview
6.8.3 Gilead Sciences Non-prescription Drugs Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Gilead Sciences Non-prescription Drugs Product Portfolio
6.8.5 Gilead Sciences Recent Developments/Updates
6.9 GlaxoSmithKline (GSK)
6.9.1 GlaxoSmithKline (GSK) Corporation Information
6.9.2 GlaxoSmithKline (GSK) Description and Business Overview
6.9.3 GlaxoSmithKline (GSK) Non-prescription Drugs Sales, Revenue and Gross Margin (2017-2022)
6.9.4 GlaxoSmithKline (GSK) Non-prescription Drugs Product Portfolio
6.9.5 GlaxoSmithKline (GSK) Recent Developments/Updates
6.10 Amgen
6.10.1 Amgen Corporation Information
6.10.2 Amgen Description and Business Overview
6.10.3 Amgen Non-prescription Drugs Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Amgen Non-prescription Drugs Product Portfolio
6.10.5 Amgen Recent Developments/Updates
6.11 AstraZeneca
6.11.1 AstraZeneca Corporation Information
6.11.2 AstraZeneca Non-prescription Drugs Description and Business Overview
6.11.3 AstraZeneca Non-prescription Drugs Sales, Revenue and Gross Margin (2017-2022)
6.11.4 AstraZeneca Non-prescription Drugs Product Portfolio
6.11.5 AstraZeneca Recent Developments/Updates
6.12 Bristol-Myers Squibb
6.12.1 Bristol-Myers Squibb Corporation Information
6.12.2 Bristol-Myers Squibb Non-prescription Drugs Description and Business Overview
6.12.3 Bristol-Myers Squibb Non-prescription Drugs Sales, Revenue and Gross Margin (2017-2022)
6.12.4 Bristol-Myers Squibb Non-prescription Drugs Product Portfolio
6.12.5 Bristol-Myers Squibb Recent Developments/Updates
6.13 Eli Lilly
6.13.1 Eli Lilly Corporation Information
6.13.2 Eli Lilly Non-prescription Drugs Description and Business Overview
6.13.3 Eli Lilly Non-prescription Drugs Sales, Revenue and Gross Margin (2017-2022)
6.13.4 Eli Lilly Non-prescription Drugs Product Portfolio
6.13.5 Eli Lilly Recent Developments/Updates
6.14 Teva
6.14.1 Teva Corporation Information
6.14.2 Teva Non-prescription Drugs Description and Business Overview
6.14.3 Teva Non-prescription Drugs Sales, Revenue and Gross Margin (2017-2022)
6.14.4 Teva Non-prescription Drugs Product Portfolio
6.14.5 Teva Recent Developments/Updates
6.15 Bayer
6.15.1 Bayer Corporation Information
6.15.2 Bayer Non-prescription Drugs Description and Business Overview
6.15.3 Bayer Non-prescription Drugs Sales, Revenue and Gross Margin (2017-2022)
6.15.4 Bayer Non-prescription Drugs Product Portfolio
6.15.5 Bayer Recent Developments/Updates
6.16 Novo Nordisk
6.16.1 Novo Nordisk Corporation Information
6.16.2 Novo Nordisk Non-prescription Drugs Description and Business Overview
6.16.3 Novo Nordisk Non-prescription Drugs Sales, Revenue and Gross Margin (2017-2022)
6.16.4 Novo Nordisk Non-prescription Drugs Product Portfolio
6.16.5 Novo Nordisk Recent Developments/Updates
6.17 Allergan
6.17.1 Allergan Corporation Information
6.17.2 Allergan Non-prescription Drugs Description and Business Overview
6.17.3 Allergan Non-prescription Drugs Sales, Revenue and Gross Margin (2017-2022)
6.17.4 Allergan Non-prescription Drugs Product Portfolio
6.17.5 Allergan Recent Developments/Updates
6.18 Takeda
6.18.1 Takeda Corporation Information
6.18.2 Takeda Non-prescription Drugs Description and Business Overview
6.18.3 Takeda Non-prescription Drugs Sales, Revenue and Gross Margin (2017-2022)
6.18.4 Takeda Non-prescription Drugs Product Portfolio
6.18.5 Takeda Recent Developments/Updates
6.19 Boehringer Ingelheim
6.19.1 Boehringer Ingelheim Corporation Information
6.19.2 Boehringer Ingelheim Non-prescription Drugs Description and Business Overview
6.19.3 Boehringer Ingelheim Non-prescription Drugs Sales, Revenue and Gross Margin (2017-2022)
6.19.4 Boehringer Ingelheim Non-prescription Drugs Product Portfolio
6.19.5 Boehringer Ingelheim Recent Developments/Updates
6.20 Takeda
6.20.1 Takeda Corporation Information
6.20.2 Takeda Non-prescription Drugs Description and Business Overview
6.20.3 Takeda Non-prescription Drugs Sales, Revenue and Gross Margin (2017-2022)
6.20.4 Takeda Non-prescription Drugs Product Portfolio
6.20.5 Takeda Recent Developments/Updates
7 Non-prescription Drugs Manufacturing Cost Analysis
7.1 Non-prescription Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Non-prescription Drugs
7.4 Non-prescription Drugs Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Non-prescription Drugs Distributors List
8.3 Non-prescription Drugs Customers
9 Non-prescription Drugs Market Dynamics
9.1 Non-prescription Drugs Industry Trends
9.2 Non-prescription Drugs Market Drivers
9.3 Non-prescription Drugs Market Challenges
9.4 Non-prescription Drugs Market Restraints
10 Global Market Forecast
10.1 Non-prescription Drugs Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Non-prescription Drugs by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Non-prescription Drugs by Type (2023-2028)
10.2 Non-prescription Drugs Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Non-prescription Drugs by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Non-prescription Drugs by Application (2023-2028)
10.3 Non-prescription Drugs Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Non-prescription Drugs by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Non-prescription Drugs by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
